Add to calendar

Please join this virtual talk with Scott Kraly, Professor of Psychology and Neuroscience.  

Use of psychiatric medications has increased dramatically during recent decades:  Approximately 35 million Americans are currently prescribed a medication to treat a diagnosed mental health problem.  Is the increasingly common use of these psychoactive drugs warranted based upon scientific evidence?

Evidence-based treatment is guided by results from experiments assessing a drug’s efficacy, and anecdotal evidence acquired from clinical practice.  The Food and Drug Administration (FDA) sets the standards for drug development, and regulates access to new medications.  FDA-sanctioned Phase 3 clinical drug trials are methodologically rigorous experiments that assess efficacy and safety of new drugs.  Results of these Phase 3 trials establish the gold-standard evidence to gain FDA approval to market a new medication (or a vaccine).  Do Phase 3 trials provide convincing evidence that predicts that a newly marketed medication will be effective and well tolerated for you or me?  What is not learned about a new medication from Phase 3 trials?  What can be done to strengthen the scientific evidence base?  How does legal off-label prescribing expand and delay development of an evidence base?  Is a newer medication always better than an older one?  In what important ways does post-marketing research improve upon the effectiveness of psychiatric medications?

Event Details

4 people are interested in this event

Virtual weblink: The webinar requires the password: nasc (all lowercase). The NASC colloquium link also requires you to have a registered Zoom account but does not require you to have a Colgate account. We are hoping these restrictions will make the talks as widely accessible as possible, while minimizing security risks.

User Activity

No recent activity

Colgate Calendar Powered by the Localist Community Event Platform © All rights reserved